脂肪干细胞移植对野百合碱诱发的肺动脉高压大鼠肺动脉压的量效和时效作用

doi:10.3877/cma.j.issn.2095-1221.2018.06.001

中华细胞与干细胞杂志(电子版) ›› 2018, Vol. 08 ›› Issue (06) : 321 -327. doi: 10.3877/cma.j.issn.2095-1221.2018.06.001

所属专题：文献；

论著

脂肪干细胞移植对野百合碱诱发的肺动脉高压大鼠肺动脉压的量效和时效作用

郑武洪¹, 罗莉¹, 李玲¹, 练桂丽¹, 许昌声¹, 王华军¹, 谢良地¹^,^†(

)

^1. 350005　福州，福建医科大学附属第一医院高血压研究所

收稿日期:2018-03-06 出版日期:2018-12-01
通信作者: 谢良地
基金资助:
国家自然科学基金面上项目(81878537、815704446、81270111)

Effects of dose and timing of adipose-derived stem cell transplantation on pulmonary arterial pressure in monocrotaline-induced pulmonary arterial hypertension in rats

Wuhong Zheng¹, Li Luo¹, Ling Li¹, Guili Lian¹, Changsheng Xu¹, Huajun Wang¹, Liangdi Xie¹^,^†()

^1. Fujian Hypertension Research Institution, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China

Received:2018-03-06 Published:2018-12-01
Corresponding author: Liangdi Xie
About author:
Corresponding author:Xie Liangdi, Email:ldxie@hotmail.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

郑武洪, 罗莉, 李玲, 练桂丽, 许昌声, 王华军, 谢良地. 脂肪干细胞移植对野百合碱诱发的肺动脉高压大鼠肺动脉压的量效和时效作用[J]. 中华细胞与干细胞杂志(电子版), 2018, 08(06): 321-327.

Wuhong Zheng, Li Luo, Ling Li, Guili Lian, Changsheng Xu, Huajun Wang, Liangdi Xie. Effects of dose and timing of adipose-derived stem cell transplantation on pulmonary arterial pressure in monocrotaline-induced pulmonary arterial hypertension in rats[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2018, 08(06): 321-327.

目的

探索脂肪干细胞（ADSC）移植治疗野百合碱（MCT）诱导的肺动脉高压（PAH）大鼠的适宜细胞数和干预时间。

方法

（1）MCT的建模时效和量效：雄性SD大鼠48只分为正常对照组，20 mg/kg、30 mg/kg、40 mg/kg MCT组分别予腹腔注射生理盐水、MCT 20 mg/kg、30 mg/kg、40 mg/kg，4和8周后，右心室插管法检测平均肺动脉压（mPAP），称重法计算右心室肥厚指数（RVHI）。（2）ADSC的治疗量效作用：雄性SD大鼠分别予腹腔注射MCT（30只）和生理盐水（30只），1周后通过颈静脉注射分别移植0.5×10⁶、1.0×10⁶、3.0×10⁶、5.0×10⁶ADSC，其他组予等量生理盐水。移植3周后检测mPAP和RVHI。（3）ADSC的治疗时效作用：雄性SD大鼠30只，分别注射40 mg/kg MCT（24只）和生理盐水（6只）。MCT腹腔注射1 d，1、2周后分别移植1.0×10⁶个ADSC。MCT注射4周后检测mPAP和RVHI。多组间比较采用单因素或双因素方差分析，两两比较采用LSD检验。

结果

（1）腹腔注射4周后，30 mg/ kg或40 mg/kg MCT组mPAP和RVHI均升高[mPAP值（24.89±3.31）mmHg，（27.19±2.11）mmHg比（15.80±0.42）mmHg，差异有统计学意义（P均< 0.05）；RVHI值0.42±0.06，0.47±0.04比0.25±0.02，差异有统计学意义（P均< 0.05）]。8周后，20 mg/kg或30 mg/ kg MCT组mPAP和RVHI均恢复正常，而40 mg/kg MCT组大鼠全部死亡。（2）40 mg/ kg MCT诱导的PAH大鼠mPAP和RVHI均升高。移植1.0×10⁶个ADSC可降低PAH大鼠的mPAP[（17.24±0.66）mmHg比（27.19±1.73）mmHg，P < 0.05]。移植0.5×10⁶、3.0×10⁶、5.0× 10⁶个ADSC不能降低PAH大鼠的mPAP和RVHI。（3）MCT腹腔注射1周和2周后，移植1.0×10⁶个ADSC可降低PAH大鼠的mPAP。

结论

40 mg/kg MCT造模4周可建立稳定的PAH大鼠模型；造模1或2周后移植1.0×10⁶个ADSC能有效降低PAH大鼠的mPAP。

关键词: 脂肪干细胞, 肺动脉高压, 野百合碱, 平均肺动脉压

Objective

To investigate the effect of dose and timing of adipose-derived stem cells (ADSC) transplantation on pulmonary arterial pressure in monocrotaline (MCT) -induced pulmonary arterial hypertension (PAH) in rats.

Methods

(1) MCT-induced PAH in rats: 48 male SD rats were injected intraperitoneally with normal saline, 20 mg/kg, 30 mg/kg and 40 mg/kg MCT respectively. Mean pulmonary arterial pressure (mPAP) was determined by right heart catheterization and right ventricular hypertrophy index (RVHI) was detected by weighting method at 4 and 8 weeks after MCT injection. (2) Dose of ADSC: male SD rats were administrated with 40 mg/kg MCT (n = 30) and normal saline (n = 30). Normal saline or different numbers of ADSC (0.5×10⁶, 1.0×10⁶, 3.0×10⁶, 5.0×10⁶) were injected through jugular vein at 1 week after intraperitoneal injection of MCT. mPAP and RVHI were detected at 3 weeks after ADSC transplantation. (3) Timing of ADSC transplantation: 30 male SD rats were administrated with 40 mg/kg MCT (n = 30) and normal saline (n = 6). One day, 1 or 2 weeks after intraperitoneal injection of 40 mg/kg MCT, 1.0×10⁶ ADSC were transplanted into the rats. mPAP and RVHI were detected at 4 weeks after MCT injection. Differences among groups were compared using one-way or two-way analysis of variance, and pairwise comparison was performed using LSD test.

Results

(1) 4 weeks after intraperitoneal injection of 30 or 40 mg/kg MCT, both mPAP and RVHI increased [mPAP (mm Hg): 24.89±3.31, 27.19±2.11 vs 15.80±0.42, P < 0.05; RVHI: 0.42±0.06, 0.47±0.04 vs 0.25±0.02, P < 0.05)]. 8 weeks after MCT injection, mPAP and RVHI returned to normal in the 20 and 30 mg/kg MCT groups. All rats died in the 40 mg/kg MCT group. (2) Both mPAP and RVHI in the 40 mg/kg MCT group elevated. 3 weeks after transplantation of 1.0×10⁶ ADSC, mPAP declined (27.19±1.73) mmHg vs (17.24±0.66) mmHg (P < 0.05). However, mPAP did not decrease in rats given 0.5×10⁶, 3.0×10⁶ or 5.0×10⁶ ADSC. (3) 1 or 2 weeks after intraperitoneal injection of 40 mg/ kg MCT, mPAP reduced in PAH rats given 1.0×10⁶ ADSC.

Conclusions

4 weeks after a single intraperitoneal injection of 40 mg/kg MCT, a stable PAH rat model could be established. 1 or 2 weeks after intraperitoneal injection of 40 mg/kg MCT, transplantation of 1.0×10⁶ ADSC could effectively reduce mPAP in PAH rats.

Key words: Adipose tissue-derived stem cell, Pulmonary arterial hypertension, Monocrotaline, Mean pulmonary arterial hypertension

图1 倒置相差显微镜下观察大鼠ADSC的细胞形态及成骨成脂分化潜能（c ~ d图为油红染色；e ~ f图为茜素红染色；×100）

表1 MCT对大鼠mPAP和RVHI影响的时效和量效作用（±s）

分组	mPAP（mmHg）		RVHI
分组	4周	8周	4周	8周
对照组	15.80±0.42	15.07±1.04	0.25±0.02	0.25±0.01
20 mg/kg MCT	21.51±2.05	18.22±0.91	0.36±0.05	0.30±0.03
30 mg/kg MCT	24.89±3.31^a	18.60±1.06	0.42±0.06^a	0.32±0.04
40 mg/kg MCT	27.19±2.11^a	-	0.47±0.04^a	-
F值	5.558	3.774	5.062	1.991
P值	0.007	0.049	0.011	0.187

表1 MCT对大鼠mPAP和RVHI影响的时效和量效作用（±s）

分组	mPAP（mmHg）		RVHI
分组	4周	8周	4周	8周
对照组	15.80±0.42	15.07±1.04	0.25±0.02	0.25±0.01
20 mg/kg MCT	21.51±2.05	18.22±0.91	0.36±0.05	0.30±0.03
30 mg/kg MCT	24.89±3.31^a	18.60±1.06	0.42±0.06^a	0.32±0.04
40 mg/kg MCT	27.19±2.11^a	-	0.47±0.04^a	-
F值	5.558	3.774	5.062	1.991
P值	0.007	0.049	0.011	0.187

表2 不同数量ADSC移植对40 mg/kg MCT诱导的PAH大鼠mPAP和RVHI的影响（±s）

ADSC数量	动物数（只）	mPAP（mmHg）		RVHI
ADSC数量	动物数（只）	对照组	PAH	对照组	PAH
0	6	15.46±0.81	27.19±1.73^a	0.25±0.01	0.46±0.03^a
0.5×10⁶	5	16.32±1.39	25.56±1.75^a	0.25±0.01	0.45±0.04^a
1.0×10⁶	5	16.79±1.19	17.24±0.66^b	0.26±0.04	0.42±0.01^a
3.0×10⁶	5	16.45±2.08	28.80±5.81^a	0.27±0.04	0.48±0.07^a
5.0×10⁶	6	16.63±0.91	29.79±2.20^a	0.25±0.01	0.50±0.05^a
F值		2.055	40.88	0.2661	83.58
P值		0.100	< 0.001	0.898	< 0.001

表2 不同数量ADSC移植对40 mg/kg MCT诱导的PAH大鼠mPAP和RVHI的影响（±s）

ADSC数量	动物数（只）	mPAP（mmHg）		RVHI
ADSC数量	动物数（只）	对照组	PAH	对照组	PAH
0	6	15.46±0.81	27.19±1.73^a	0.25±0.01	0.46±0.03^a
0.5×10⁶	5	16.32±1.39	25.56±1.75^a	0.25±0.01	0.45±0.04^a
1.0×10⁶	5	16.79±1.19	17.24±0.66^b	0.26±0.04	0.42±0.01^a
3.0×10⁶	5	16.45±2.08	28.80±5.81^a	0.27±0.04	0.48±0.07^a
5.0×10⁶	6	16.63±0.91	29.79±2.20^a	0.25±0.01	0.50±0.05^a
F值		2.055	40.88	0.2661	83.58
P值		0.100	< 0.001	0.898	< 0.001

图2 PAH大鼠移植ADSC后发生肺梗塞

表3 不同移植时间、不同治疗周期的ADSC对PAH大鼠mPAP和RVHI的影响（±s）

分组	动物数（只）	mPAP（mmHg）	RVHI
对照组	6	14.76±0.81	0.26±0.01
PAH组	5	27.19±2.11^a	0.46±0.03^a
A1d组	6	24.48±4.24^a	0.49±0.06^a
A1W组	5	17.24±0.81^b	0.42±0.00^a
A2W组	6	20.27±0.49^b	0.42±0.01^a
F值		4.891	9.038
P值		0.005	< 0.001

表3 不同移植时间、不同治疗周期的ADSC对PAH大鼠mPAP和RVHI的影响（±s）

分组	动物数（只）	mPAP（mmHg）	RVHI
对照组	6	14.76±0.81	0.26±0.01
PAH组	5	27.19±2.11^a	0.46±0.03^a
A1d组	6	24.48±4.24^a	0.49±0.06^a
A1W组	5	17.24±0.81^b	0.42±0.00^a
A2W组	6	20.27±0.49^b	0.42±0.01^a
F值		4.891	9.038
P值		0.005	< 0.001

1	Lai YC, Potoka KC, Champion HC, et al. Pulmonary arterial hypertension the clinical syndrome[J]. Circ Res, 2014,115(1):115-130.
2	Strem BM, Hicok KC, Zhu M, et al. Multipotential differentiation of adipose tissue-derived stem cells[J]. Keio J Med, 2005,54(3): 132-141.
3	Konno M, Hamabe A, Hasegawa S, et al. Adipose-derived mesenchymal stem cells and regenerative medicine[J]. Dev Growth Differ, 2013, 55(3):309-318.
4	Eguchi M, Ikeda S, Kusumoto S, et al. Adipose-derived regenerative cell therapy inhibits the progression of monocrotaline-induced pulmonary hypertension in rats[J]. Life Sci, 2014, 118(2): 306-312.
5	梁敏烈，谢良地，李宏亮, 等. 脂肪间充质干细胞早期干预对野百合碱诱发的肺动脉高压大鼠肺小动脉功能的影响[J]. 中国病理生理杂志, 2013, 29(10):1729-1735.
6	郑苏梨，谢良地，李宏亮, 等. 脂肪间充质干细胞对野百合碱诱发的肺动脉高压大鼠肺动脉钙离子通道的影响[J]. 中国病理生理杂志, 2013, 29(6):961-968.
7	梁敏烈，谢良地，李宏亮, 等. 脂肪间充质干细胞延迟干预对野百合碱诱发的肺动脉高压大鼠肺小动脉功能的影响[J]. 中华高血压杂志, 2013, 29(9):731-737.
8	Liang M, Li H, Zheng S, et al. Comparison of early and delayed transplantation of adipose tissue-derived mesenchymal stem cells on pulmonary arterial function in monocrotaline-induced pulmonary arterial hypertensive rats[J]. European Heart Journal Supplements, 2015, 17(suppl_F):F4-F12.
9	Luo L, Lin T, Zheng S, et al. Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats[J]. Clin Exp Hypertens, 37(3):241-248.
10	Luo L, Zheng W, Lian G, et al. Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway[J]. Int J Mol Med, 41(1):51-60.
11	Tofovic SP, Salah EM, Mady HH, et al. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats[J]. J Cardiovasc Pharmacol, 2005, 46(4):430-437.
12	Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension[J]. Am J Physiol, 1988, 255(6 Pt 2):H1484-1491.
13	Lalich JJ, Merkow L. Pulmonary arteritis produced in rat by feeding crotalaria spectabilis[J]. Lab Invest, 1961, 10: 744-750.
14	Kay JM, Harris P, Heath D. Pulmonary hypertension produced in rats by ingestion of crotalaria spectabilis seeds[J]. Thorax, 1967, 22(2):176-179.
15	Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the international federation for adipose therapeutics and science (ifats) and the international society for cellular therapy (isct)[J]. Cytotherapy, 2013, 15(6):641-648.
16	Vaillancourt M, Ruffenach G, Meloche J, et al. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension[J]. Can J Cardiol, 2015, 31(4):407-415.
17	Jungmann PM, Mehlhorn AT, Schmal H, et al. Nanomechanics of human adipose-derived stem cells: Small gtpases impact chondrogenic differentiation[J]. Tissue Eng Part A, 2012, 18(9-10):1035-1044.
18	Bartunek J, Wijns W, Heyndrickx GR, et al. Timing of intracoronary bone-marrow-derived stem cell transplantation after st-elevation myocardial infarction[J]. Nat Clin Pract Cardiovasc Med, 2006, 3 Suppl 1: S52-56.
19	Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(4):L363-369.

[1]	刘锐, 郭思佳, 井维斌, 马明明, 曹卫红. 人源性脂肪干细胞对30%体表总面积Ⅲ度烫伤大鼠肺组织炎症反应的影响及其机制初步探讨[J]. 中华危重症医学杂志(电子版), 2022, 15(06): 441-447.
[2]	伏洪玲, 刘瀚旻. 支气管肺发育不良及肺动脉高压有关信号通路研究现状[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(05): 497-505.
[3]	贾蔓箐, 卞婧, 周业平. 对小剂量胰岛素局部注射促进脂肪干细胞移植成活及改善糖尿病创面愈合临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(04): 312-316.
[4]	吴丽娜, 魏林, 曾志贵, 张梁, 何恩辉, 檀玉乐, 朱志军, 孙丽莹. 肺动脉高压靶向药物联合肝移植治疗重度门脉性肺动脉高压一例[J]. 中华移植杂志(电子版), 2022, 16(06): 376-378.
[5]	郑珊珊, 郑哲, 黄洁, 廖中凯, 宋云虎, 房晓楠, 刘盛. 主动脉内球囊反搏作为心脏移植桥接治疗对晚期心力衰竭合并肺动脉高压患者的疗效[J]. 中华移植杂志(电子版), 2022, 16(05): 277-284.
[6]	代芬, 卞士柱. 无创机械通气联合肺康复在肺动脉高压呼吸衰竭治疗中的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 560-562.
[7]	李丹阳, 李满祥. 肠道菌群失调在肺动脉高压发病中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 432-434.
[8]	张璐, 卞士柱. 肺动脉高压患者药物治疗依从性及健康管理分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 107-109.
[9]	任成山, 卞士柱, 胡明冬. 肺动脉高压的成因及治疗新理念[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 1-5.
[10]	代芬, 卞士柱. Ⅰ期心脏运动康复在肺动脉高压患者中的临床意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 721-723.
[11]	李彩霞, 彭丽娜. 血浆ADMA联合BNP与慢性阻塞性肺疾病并发肺动脉高压的相关性分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 545-547.
[12]	郝卓伦, 齐雯丽, 孙家明, 周牧冉, 郭能强. 脂肪干细胞促进慢性创面愈合的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(04): 237-242.
[13]	乔梁, 杨向群. 脂肪干细胞在心肌损伤修复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(04): 230-236.
[14]	余林阳, 王美英, 李建斌, 楼骁斌, 谢思远, 马志忠, 齐海英, 李稼. 高原地区肺炎合并右心功能衰竭体征患儿的肺动脉压力和心脏形态与功能的特征[J]. 中华临床医师杂志(电子版), 2023, 17(05): 535-544.
[15]	王金志, 陶新曹, 谢万木, 傅志辉, 赵蕴伟, 黄强, 翟振国. 球囊肺动脉成形术在慢性血栓栓塞性肺动脉高压治疗中的进展[J]. 中华介入放射学电子杂志, 2023, 11(03): 262-267.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effects of dose and timing of adipose-derived stem cell transplantation on pulmonary arterial pressure in monocrotaline-induced pulmonary arterial hypertension in rats

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effects of dose and timing of adipose-derived stem cell transplantation on pulmonary arterial pressure in monocrotaline-induced pulmonary arterial hypertension in rats